Power Law company profile

AlloVir

Biotech & Life Sciences · Lincoln, United States · Founded 2013 · IPO 2020 Unicorn

Developing cellular immunotherapies for severe viral infections

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

8 investors on AlloVir's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 8 investors entered at this stage

Fidelity Investments

EcoR1 Capital

Invus

F2 Ventures

Transformation Capital

Redmile Group

Epitherapeutics

Samsara BioCapital

Global footprint

Where AlloVir has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States91.5%

🇮🇪 Ireland7.2%

🇨🇭 Switzerland5.6%

3 countries shown

Web traffic by country

230 monthly visits
across markets

🇺🇸 United States87%

Top 1 markets shown

Patent intelligence

$4M patent portfolio · 2 active families

Estimated portfolio value

$4M

548.9× smaller than top peer Ablynx ($2B)

2 active patent families

Where AlloVir innovates Molecular biologyT cellPathologyTransplant recipientViremia

Where AlloVir concentrates vs peers

Each axis is a top-10 topic across AlloVir and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about AlloVir

An AI-synthesized read of the highest-engagement posts about AlloVir on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AlloVir on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles